Care of depressed patients with anxiety symptoms
- PMID: 10446738
Care of depressed patients with anxiety symptoms
Abstract
Anxiety frequently coexists with depression, either as a comorbid anxiety disorder or as anxiety symptoms accompanying a primary depressive disorder. Effective therapy for the treatment of depressive illness must include a consideration of anxiety symptoms, since anxiety has been estimated to be present in up to 96% of patients with depressive illness. Available data also indicate that depressed patients with significant anxiety may be at greater risk for suicide. Of particular clinical importance are symptoms of somatic anxiety: they are present in up to 86% of depressed patients, and the failure to treat them effectively can diminish the ability of a patient to function. Since the overall prognosis for recovery from a major depressive episode is less than optimal in patients with significant anxiety, treatments that can provide an effective and early relief of both depressive and anxiety symptoms are of paramount importance. Drugs with serotonin reuptake inhibition (such as selective serotonin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs]) may produce transient increases in anxiety symptomatology presenting as jitteriness, agitation, insomnia, and gastrointestinal symptoms when treatment is initiated. Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment. The available data show that mirtazapine is superior to placebo in depressed patients with high baseline anxiety and/or agitation. Furthermore, mirtazapine was statistically significantly superior to both citalopram and paroxetine in alleviating anxiety symptoms early in treatment as assessed by changes from baseline on the Hamilton Rating Scale for Anxiety or the Hamilton Rating Scale for Depression anxiety/somatization factor, respectively. Mirtazapine provides early and effective relief of both depressive and anxiety symptoms, reducing the need for polypharmacy. These therapeutic actions of mirtazapine persist throughout the course of treatment.
Similar articles
-
Mirtazapine versus selective serotonin reuptake inhibitors.J Clin Psychiatry. 1999;60 Suppl 17:18-22; discussion 46-8. J Clin Psychiatry. 1999. PMID: 10446737 Review.
-
Antidepressant treatment of the depressed patient with insomnia.J Clin Psychiatry. 1999;60 Suppl 17:28-31; discussion 46-8. J Clin Psychiatry. 1999. PMID: 10446739 Review.
-
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.J Clin Psychiatry. 2004 Oct;65(10):1394-9. doi: 10.4088/jcp.v65n1015. J Clin Psychiatry. 2004. PMID: 15491244 Clinical Trial.
-
A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.J Clin Psychiatry. 2003 Aug;64(8):921-6. doi: 10.4088/jcp.v64n0810. J Clin Psychiatry. 2003. PMID: 12927007 Clinical Trial.
-
Does mirtazapine have a more rapid onset than SSRIs?J Clin Psychiatry. 2001 May;62(5):358-61. doi: 10.4088/jcp.v62n0509. J Clin Psychiatry. 2001. PMID: 11411818
Cited by
-
The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice.Eur Arch Psychiatry Clin Neurosci. 2016 Dec;266(8):725-736. doi: 10.1007/s00406-016-0684-7. Epub 2016 Mar 22. Eur Arch Psychiatry Clin Neurosci. 2016. PMID: 27002521 Free PMC article. Review.
-
Panic Attacks During Escalation of Mirtazapine.Prim Care Companion J Clin Psychiatry. 2003 Apr;5(2):93. doi: 10.4088/pcc.v05n0208. Prim Care Companion J Clin Psychiatry. 2003. PMID: 15156239 Free PMC article. No abstract available.
-
Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.Psychopharmacology (Berl). 2023 Aug;240(8):1615-1628. doi: 10.1007/s00213-023-06412-9. Epub 2023 Jul 5. Psychopharmacology (Berl). 2023. PMID: 37407727 Free PMC article.
-
Scared to Trust? - Predicting Trust in Highly Automated Driving by Depressiveness, Negative Self-Evaluations and State Anxiety.Front Psychol. 2020 Jan 23;10:2917. doi: 10.3389/fpsyg.2019.02917. eCollection 2019. Front Psychol. 2020. PMID: 32038353 Free PMC article.
-
Escitalopram : a review of its use in the management of major depressive and anxiety disorders.CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004. CNS Drugs. 2003. PMID: 12665392 Review.